Charles River Laboratories (CRL) reported Q1 2026 sales of $995.8 million and a non-GAAP profit of $2.06 per share, both of which exceeded market expectations. However, the company is contending with pressures on its profit margins, as it experienced a 1.5% year-on-year decline in organic revenue. In response to its robust performance, CRL has raised its full-year adjusted EPS guidance to $11.05 at the midpoint and signed a significant MOU with MEDIPOST to enhance GMP testing solutions.
“Charles River Laboratories · reported · Q1 CY2026 results · topping the market’s revenue expectations”
“Charles River Laboratories · reported · sales · $995.8 million”
“Charles River Laboratories · reported · non-GAAP profit · $2.06 per share”
“Charles River Laboratories · reported · adjusted EBITDA · $214.5 million”
“Charles River Laboratories · raised · full-year Adjusted EPS guidance · $11.05 at the midpoint”
“Charles River Laboratories · reported · Organic Revenue · fell 1.5% year on year”
“Charles River Laboratories · stated · Market Capitalization · $8.96 billion”
“Charles River Laboratories · is investing · in digital platforms and AI · to streamline operations”
“Charles River Laboratories · generated · revenues from Canada · $109.57 million”
“Charles River Laboratories · is a · company · true”
“Charles River Laboratories · has · industry · Biotechnology Research”
“Charles River Laboratories · has · company size · 10,001+ employees”
